409,428 Shares in Bristol Myers Squibb Company $BMY Purchased by Cibc World Market Inc.

Key Points

• Cibc World Market Inc. purchased 409,428 Bristol Myers Squibb shares during the second quarter, valued at approximately $23.6 million. Institutional investors collectively own 76.41% of BMY’s outstanding stock.
• Bristol Myers Squibb reported quarterly revenue of $12.97 billion and earnings of $2.04 per share, exceeding analyst expectations, while revenue increased 5.7% year over year.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and a $66.06 price target. However, generic competition against legacy products remains a key risk, despite support from Eliquis and newer pipeline programs.

Cibc World Market Inc. bought a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 409,428 shares of the biopharmaceutical company's stock, valued at approximately $23,591,000.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Bristol Myers Squibb by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company's stock worth $10,719,376,000 after purchasing an additional 2,743,759 shares during the period. BlackRock Inc. increased its holdings in Bristol Myers Squibb by 5.1% during the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock valued at $10,393,783,000 after buying an additional 8,702,106 shares during the period. State Street Corp raised its stake in Bristol Myers Squibb by 1.4% in the fourth quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company's stock worth $5,285,065,000 after buying an additional 1,385,206 shares in the last quarter. Geode Capital Management LLC raised its stake in Bristol Myers Squibb by 13.1% in the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company's stock worth $2,837,026,000 after buying an additional 6,084,046 shares in the last quarter. Finally, Norges Bank purchased a new stake in Bristol Myers Squibb during the fourth quarter worth $1,947,272,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb plans to invest approximately $2.3 billion in a new Houston manufacturing facility, part of a broader $40 billion U.S. investment commitment. The project reinforces BMY’s confidence in domestic production capacity and could support long-term operational growth. Bristol-Myers Squibb Bets $2.3 Billion on Texas
• Positive Sentiment: BMY is collaborating with Chai Discovery on artificial-intelligence-driven antibody discovery. The partnership could help identify novel therapeutic candidates more efficiently and strengthens the company’s efforts to modernize its drug-development platform. Chai Discovery Collaboration
• Positive Sentiment: The company is launching a Phase 1 study of an early Alzheimer’s disease antibody. Although the program remains highly experimental, it adds another potential long-term growth opportunity to BMY’s pipeline. Early Alzheimer’s Antibody Study
• Positive Sentiment: Strong Eliquis performance is helping offset declines in BMY’s older products facing generic pressure, supporting a more favorable 2026 revenue outlook. Elevated call-option activity also signals increased bullish interest, though it is not a fundamental guarantee. Eliquis and Legacy Portfolio Analysis
• Neutral Sentiment: Early clinical work on navlimetostat shows continued pipeline activity, but the Phase 1-stage program has not yet produced efficacy data that would materially change near-term earnings expectations. Navlimetostat Study Update
• Negative Sentiment: Generic competition remains a key risk for BMY’s legacy portfolio. Investors must determine whether Eliquis growth and newer pipeline assets can replace revenue lost as established medicines face erosion. Legacy Portfolio Erosion Analysis

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on BMY. Bank of America cut their price target on Bristol Myers Squibb from $67.00 to $66.00 and set a "buy" rating on the stock in a report on Friday, July 10th. Raymond James Financial began coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a "strong-buy" rating for the company. Piper Sandler began coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They set an "overweight" rating on the stock. Guggenheim reiterated a "buy" rating and issued a $75.00 target price (up from $72.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Finally, Weiss Ratings raised shares of Bristol Myers Squibb from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Tuesday, August 18th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $66.06.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $67.06 on Monday. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $68.64. The business's fifty day simple moving average is $60.55 and its 200-day simple moving average is $59.39. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The company has a market cap of $136.98 billion, a PE ratio of 14.77, a PEG ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts' consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm had revenue of $12.97 billion during the quarter, compared to analysts' expectations of $11.74 billion. During the same quarter last year, the firm earned $1.46 EPS. The business's quarterly revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Analysts expect that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were paid a dividend of $0.63 per share. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.8%. Bristol Myers Squibb's payout ratio is presently 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source